Company profile

Sciwind Biosciences

Peptide therapeutics (obesity/metabolic)

Privately held: no public share price · China

Assets

(3 total)
3Total Assets
1Approved
1Phase 3 / Filed
1Phase 1–2 / Early
2Diseases
Quick filter:
Showing 3 of 3 assets
Target & Modality
ecnoglutide
Approved
GLP-1 receptorPeptide
Obesity
XW003
Phase 3
GLP-1 receptorPeptide
Obesity
XW014
Phase 1
GLP-1 receptorSmall molecule
Type 2 Diabetes

Upcoming events

Research

Unlock the company readout calendar

Research includes estimated primary-completion dates, earnings report dates, and 'What to watch' trial analysis across this company’s pipeline.

Financial reports

Research

Unlock sourced financial history

Research includes quarterly, interim and annual revenue, R&D, cash and burn figures linked to the underlying company reports.

Educational data tool. Figures are sourced from company filings and press releases: see each row's filing link. Share price is delayed (~15min) and refreshed periodically, not a real-time feed.